Literature DB >> 11388949

Bipolar disorder: leads from the molecular and cellular mechanisms of action of mood stabilisers.

H K Manji1, G J Moore, G Chen.   

Abstract

Background New research is dramatically altering our understanding of the molecular mechanisms underlying neuronal communication. Aim To elucidate the molecular mechanisms underlying the therapeutic effects of mood stabilisers. Method Results from integrated clinical and laboratory studies are reviewed. Results Chronic administration of lithium and valproate produced a striking reduction in protein kinase C (PKC) isozymes in rat frontal cortex and hippocampus. In a small study, tamoxifen (also a PKC inhibitor) had marked antimanic efficacy. Both lithium and valproate regulate the DNA binding activity of the activator protein 1 family of transcription factors. Using mRNA differential display, it was also shown that chronic administration of lithium and valproate modulates expression of several genes. An exciting finding is that of a robust elevation in the levels of the cytoprotective protein, bcl-2. Conclusions The results suggest that regulation of signalling pathways may play a major part in the long-term actions of mood stabilisers. Additionally, mood stabilisers may exert underappreciated neuroprotective effects.

Entities:  

Year:  2001        PMID: 11388949

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  6 in total

Review 1.  Impact of molecular medicine on neuropsychiatry: the clinician's perspective.

Authors:  J M Ryan; R Loy; P N Tariot
Journal:  Curr Psychiatry Rep       Date:  2001-10       Impact factor: 5.285

2.  Recurrent catatonia treated with lithium and carbamazepine: a series of 2 cases.

Authors:  Susanta K Padhy; Bn Subodh; Rahul Bharadwaj; K Arun Kumar; Suresh Kumar; Mk Srivastava
Journal:  Prim Care Companion CNS Disord       Date:  2011

Review 3.  Olanzapine: a review of its use in the treatment of bipolar I disorder.

Authors:  N Bhana; C M Perry
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

4.  Replicable differences in preferred circadian phase between bipolar disorder patients and control individuals.

Authors:  Joel Wood; Boris Birmaher; David Axelson; Mary Ehmann; Catherine Kalas; Kelly Monk; Scott Turkin; David J Kupfer; David Brent; Timothy H Monk; Vishwajit L Nimgainkar
Journal:  Psychiatry Res       Date:  2009-03-10       Impact factor: 3.222

5.  State-related differences in the level of psychomotor activity in patients with bipolar disorder - Continuous heart rate and movement monitoring.

Authors:  Maria Faurholt-Jepsen; Søren Brage; Maj Vinberg; Lars Vedel Kessing
Journal:  Psychiatry Res       Date:  2016-01-22       Impact factor: 3.222

6.  Exploring lithium's transcriptional mechanisms of action in bipolar disorder: a multi-step study.

Authors:  Ibrahim A Akkouh; Silje Skrede; Asbjørn Holmgren; Kari M Ersland; Lars Hansson; Shahram Bahrami; Ole A Andreassen; Vidar M Steen; Srdjan Djurovic; Timothy Hughes
Journal:  Neuropsychopharmacology       Date:  2019-10-25       Impact factor: 7.853

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.